4-羧基-2-羟基丁酸甲酯 | 100813-25-0

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 4-羧基-2-羟基丁酸甲酯
• 英文名称: methyl 4-carboxy-2-hydroxybutanoate
• 英文别名: 4-Hydroxy-5-methoxy-5-oxopentanoic acid
• CAS: 100813-25-0
• 化学式: C₆H₁₀O₅
• 分子量: 162.142
• InChiKey: NXXFVFBJXDHVRC-UHFFFAOYSA-N

物化性质

• 熔点：
  45-46 °C
• 沸点：
  350.9±32.0 °C(Predicted)
• 密度：
  1.312±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.6
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  83.8
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  重氮甲烷 、 4-羧基-2-羟基丁酸甲酯 以 正己烷 为溶剂， 生成 dimethyl α-hydroxyglutarate
  参考文献：
  名称：

  Dye-sensitized photooxygenation of 1,2-cyclopentanediones in methanol

  摘要：

  DOI：

  10.1021/jo00357a042
• 作为产物：
  描述：

  2-羟基-2-环戊烯-1-酮 生成 4-羧基-2-羟基丁酸甲酯
  参考文献：
  名称：

  UTAKA, MASANORI;NAKATANI, MANABU;TAKEDA, AKIRA, J. ORG. CHEM., 1986, 51, N 7, 1140-1141

  摘要：

  DOI：

文献信息

• [EN] A PROCESS FOR THE PREPARATION OF ROSUVASTATIN INTERMEDIATE<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION D'UN INTERMÉDIAIRE DE LA ROSUVASTATINE
  申请人：TEVA PHARMA

  公开号：WO2011106546A1

  公开（公告）日：2011-09-01

  Processes utilizing treatment with Candida Antarctica lipase B ("CAL-B") or Candida Antarctica lipase A ("CAL-A") for desymmetiϊzation of a prochiral di-ester compound of formula (I): wherein R is a C1-C4 alkyl group, R1 is a hydrogen; a C1-C4 acyl, preferably acetyl, propanoyl or butyryl; or a C1-C6 alkyl group, preferably methyl or ethyl, and n is 1, 2 or 3, to prepare the corresponding optically pure (S)-mono-ester according to formula (II).

  使用Candida Antarctica脂肪酶B（“CAL-B”）或Candida Antarctica脂肪酶A（“CAL-A”）处理的过程，用于对式（I）的非对称二酯化合物进行去对称化，其中R是C1-C4烷基，R1是氢; C1-C4酰基，优选为乙酰基，丙酰基或丁酰基; 或C1-C6烷基，优选为甲基或乙基，n为1，2或3，以制备相应的光学纯（S）-单酯，其化学式为（II）。
• KETONE DERIVATIVES AND MEDICINAL USE THEREOF
  申请人：TORAY INDUSTRIES, INC.

  公开号：EP0841063A1

  公开（公告）日：1998-05-13

  The present invention relates to ketone derivatives represented by the following formula and medical agents cotaining the ketone derivatives or pharmacologically acceptable salts thereof as an active ingredient, and in particular, relates to a hematopoietic agent; it is shown that the present invention increases blood cells, such as platelets, white blood cells, and red blood cells, and is effective in preventing and treating cytopenia caused by cancer chemotherapy, radiation therapy, and the like.

  本发明涉及下式所代表的酮衍生物和以酮衍生物或其药理学上可接受的盐作为活性成分的医用制剂，特别是涉及一种造血制剂；本发明可增加血小板、白细胞和红细胞等血细胞，对预防和治疗癌症化疗、放疗等引起的细胞减少症有效。
• A compound for re-equilibrating the intestinal bacterial flora with an antidiarrhoeic, anti-inflammatory and lentive activity against lactose and lactose derivative intolerances
  申请人：Farmaceutici S.R.L.

  公开号：EP1985300A2

  公开（公告）日：2008-10-29

  A compound for a compound for re-equilibrating the intestinal bacterial flora with an anti-diarrhoeic, anti-inflammatory and lenitive activity against lactose and lactose derivative intolerances, characterized in that said compound comprises a compound base including Lactobacillus Sporogenes bacteric cells.

  一种用于重新平衡肠道细菌菌群的化合物，对乳糖和乳糖衍生物不耐受症具有抗腹泻、抗炎和宽松活性，其特征在于所述化合物由包括孢子乳杆菌细菌细胞的复合基质组成。
• New lipoxygenase and cholinesterase inhibitory sphingolipids from <i>Carthamus oxyacantha</i>
  作者：Muhammad Dilshad、Naheed Riaz、Muhammad Saleem、Nusrat Shafiq、Muhammad Ashraf、Tayaba Ismail、Hafiza Mehwish Rafiq、Abdul Jabbar

  DOI：10.1080/14786419.2015.1075524

  日期：2016.8.17

  Two new sphingolipids: oxyacanthin A [(2S,3S,4R)-2-[(2R,5E)-2-hydroxyoctadec-5-enoyl]amino}hexaeicosane-1,3,4-triol; 1] and B [(2S,3S,4R)-2-[(2R,5E)-2-hydroxyoctadec-5-enoyl]amino}hexaeicosane-1,3,4-triol-1-O-beta-D-glucopyranoside; 2], together with 1-octacosanol, -sitosterol, -sitosterol 3-O-beta-D-glucopyranoside and luteolin 7-O-beta-glucopyranoside were isolated from the methanolic extract of the whole plant of Carthamus oxyacantha. Their structures were elucidated using H-1 and C-13 NMR spectra and 2D NMR analyses (HMQC, HMBC and COSY) in combination with mass spectrometry (EI-MS, HR-EI-MS, FAB-MS and HR-FAB-MS) experiments and in comparison with the literature data of the related compounds. Both the compounds 1 and 2 showed inhibitory potential against lipoxygenase (LOX) in a concentration-dependent manner with IC50 values 83.3 +/- 1.3 and 245.7 +/- 1.1 mu M, whereas compound 2 showed inhibition against enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) with IC50 values 65.3 +/- 0.1 and 93.6 +/- 0.1 mu M, respectively.[GRAPHICS].
• US6215016B1
  申请人：——

  公开号：US6215016B1

  公开（公告）日：2001-04-10